The next big revolution in radiology isn’t coming — it’s already here. And it’s happening at the molecular level, where imaging is transforming from a diagnostic tool into a precision weapon against disease. But here’s where it gets truly fascinating: this new frontier could blur the lines between detecting illness and curing it.
Speaking at the opening session of the RSNA annual meeting in Chicago on November 30, RSNA President Dr. Umar Mahmood, MD, PhD, delivered a bold vision for the future of medical imaging. He declared that molecular imaging will be a cornerstone of precision medicine, with radiologists leading the charge in tailoring treatments for every patient.
“Radiology today is nothing like it was a decade ago,” Mahmood told the audience. “And thanks to our collective progress, it’ll look entirely different again 10 years from now.”
As the chief of Nuclear Medicine and Molecular Imaging and director of the Center for Precision Imaging at Massachusetts General Hospital, Mahmood brings both leadership and deep expertise to the topic. He also holds a professorship at Harvard Medical School in Boston and has contributed to RSNA in multiple capacities since joining its Board of Directors in 2017. His resume includes leading roles with the RSNA Research & Education Foundation, the NIH Clinical Center, the American College of Radiology (ACR), and the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
So what exactly makes molecular imaging so revolutionary? Mahmood explained that clinicians can now visualize lymph node metastases as small as 2 millimeters in prostate cancer by using prostate-specific membrane antigen (PSMA)-targeted PET imaging. This unprecedented precision, he noted, not only enhances diagnosis but also shapes real-time treatment decisions for individual patients.
And here’s the part that could change everything: the field is moving beyond dozens of detectable abnormalities to potentially hundreds of molecular targets. The implications for oncology and personalized therapy are staggering.
Mahmood described the concept of theranostics — an approach that fuses therapy and diagnostics into one. By substituting just a single radioactive atom in a compound, scientists can transform an imaging tracer into a molecule that delivers a targeted dose of radiation directly to a tumor. In essence, what once showed the problem can now help solve it.
But to make this ambitious future workable, Mahmood emphasized, radiology leaders must create frameworks that simplify how massive amounts of molecular data are used. He highlighted two main strategies: grouping data into broader, actionable categories and applying artificial intelligence to refine treatment selection.
He further noted that radiologists are often the first to see how cutting-edge therapies interact with living tissue. Their expertise is essential for monitoring responses to innovations like oncolytic viruses, CRISPR-based gene editing, tumor vaccines, and CAR-T therapies. Through sophisticated imaging, doctors can watch these treatments in action, revealing what works — and what doesn’t — in real time.
“Every radiology subspecialty plays a vital role in these extraordinary breakthroughs for our patients,” Mahmood affirmed.
He closed his address by expressing gratitude to his family, colleagues, and mentors who supported him through his tenure as RSNA president and board member, as well as throughout his scientific career.
Molecular imaging, it seems, isn’t just redefining radiology — it’s redefining the very concept of medicine itself. But do you believe combining diagnostics and therapy into one molecular-level tool is the right direction for the future of healthcare? Or does this level of personalization risk overcomplicating patient care? Share your thoughts in the comments.
For full coverage of RSNA 2025 discussions and discoveries, visit RADCast at https://www.auntminnie.com/resources/conference/rsna/2025.
